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We report here the genetic cause of the X-linked syndrome of psychosis, pyramidal signs, and macro-orchidism
(PPM-X) in a three-generation family manifesting the disorder as a mutation in the methyl-CpG binding–protein
2 (MECP2) gene in Xq28. The A140V mutation was found in all affected males and all carrier females in the
family. To date, descriptions have been published of two patients with independent familial mental retardation
(MR) and two patients with sporadic MR who harbor this specific mutation in the MECP2 gene. This strongly
suggests that A140V is a hot spot of mutation resulting in moderate to severe MR in males. A simple and reliable
PCR approach has been developed for detection of the hot spot A140V mutation to prescreen any other unexplained
cases of MR before further extensive mutation analyses.
X-linked mental retardation (XLMR) is estimated to
cause 14% of all MR, corresponding to ∼3 cases per
1,000 births (Stevenson 2000). Among the ∼130 XLMR
syndromes described, 25 gene loci have been identified
and 55 further loci mapped. Regional assignment of dif-
ferent X-linked forms of MR was possible by identifi-
cation of large families. Lindsay et al. (1996) presented
a three-generation family withMR andmanic-depressive
psychosis, as well as pyramidal signs, parkinsonian fea-
tures, and macro-orchidism, which is classified as the
PPM-X syndrome (PPMX [MIM 300055]). Extensive
linkage analysis mapped the PPM-X locus to Xq28, a
region harboring three known genes (RabGDI1, FMR2,
and MECP2) involved in XLMR syndromes.
Following up on the first report (Amir et al. 1999),
several studies have shown mutations in the MECP2
gene located in Xq28 in patients with Rett syndrome
(RTT [MIM 312750]) (for review, see Amir and Zoghbi
2000; Buyse et al. 2000; Bourdon et al. 2001), a sporad-
ic severe neurological disorder occurring almost exclu-
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sively in females. Heterozygous mutations in MECP2
are found in as many as 80% of sporadic RTT cases.
Mutations in males were thought to be lethal but have
been described in rare cases of neonatal encephalopathy
in children born into families with RTT (Schanen and
Francke 1998; Schanen et al. 1998; Sirianni et al. 1998;
Villard et al. 2000) and in one case of somatic mosaicism
(Clayton-Smith et al. 2000). The wide spectrum of phe-
notypic variability in RTT is correlated with mutation
type and location in the MECP2 gene (Wan et al. 1999;
Cheadle et al. 2000) and possibly the pattern of X-in-
activation (Amir et al. 2000). Recently, investigations of
males with severe MR identified seven different muta-
tions (Meloni et al. 2000; Orrico et al. 2000; Couvert
et al. 2001), suggesting that theMECP2 gene is a strong
candidate for XLMR. In addition, an individual with
mild nonspecific MR who harbors an in-frame deletion
in the MECP2 gene has been described (Yntema et al.
2002).
In the context of an ongoing examination of candidate
genes for the PPM-X syndrome, mutation screening was
performed in CLIC2, RabGDI1, and IRAK, and the re-
sults excluded these genes (data not shown). Conse-
quently, screening of theMECP2 gene was performed by
direct sequencing of six PCR fragments covering the entire
coding region, using combinations of primer pairs de-
scribed elsewhere (Amir et al. 1999; Buyse et al. 2000),
which are available upon request. We found a CrT tran-
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Figure 1 Segregation of the mutation C419T in the family with PPM-X. A, Pedigree of part of the family. A square with the right half
blackened represents an affected male with MR. A blackened square represents an affected male with MR and manic-depressive illness. A circle
with a dot represents an obligate carrier female. B, PCR-RFLP assay for mutation detection. AccI-digested PCR products from exon 4, using
the primers 4amod (5′-CGCCTACCTTTTCGAAGTAT-3′) and 4a-For.2 (5′-CGCTCTGCCCTATCTCTGA-3′, were separated on a 3% agarose
gel; primers are modifications of those described by Buyse et al. [2000]) at an annealing temperature of 65C. The modified forward primer
4amod, together with the CrT transition in position 419 (nucleotides numbered from the first base of the translation-initiation ATG codon;
GenBank accession number X99686), creates an AccI restriction site generating two fragments of 118 bp and 18 bp from the 136-bp PCR
product; because of its small size, the 18-bp digestion product is not visible on this agarose gel. M p molecular weight marker V (Roche). C,
direct sequencing of the mutation 419CrT found in the family: II-3, carrier female (heterozygote 419C/T); III-7, affected male (hemizygote
419T); III-8, unaffected male (hemizygote 419C).
sition at position 419 in exon 4 (nucleotides numbered
from the first base of the translation-initiationATGcodon
[GenBank accession number X99686]). The transition re-
sulted in an A140V mutation in the first two members of
the family with PPM-X to be screened (the affected in-
dividuals (II-6 and III-7 in fig. 1A). This specific mutation
has been described already in a family with severe MR
in males (Orrico et al. 2000) and in two individuals with
sporadic MR (Couvert et al. 2001). Subsequently, seg-
regation analysis of the mutation in the family was per-
formed on all available DNA samples, by development
of a fast and reliable PCR-RFLP assay for the 419CrT
(A140V) mutation using a modified forward primer
4amod and the published primer 4a-For.2 (Buyse et al.
2000), creating an AccI restriction site if the mutation is
existent (fig. 1B). The A140V mutation was present in all
affected individuals of the family and all female carriers
under investigation, including the founder female I-1, but
was absent in unaffected individuals II-13 (not included
in the original published pedigree [Lindsay et al. 1996])
and II-17. To verify the results of the PCR-RFLP assay,
the site of mutation was sequenced in all available DNA
samples. Figure 1C shows electropherograms of carrier
female II-3 and the affected male III-7 and his unaffected
brother III-8. When the PCR-RFLP assay was used, the
419CrTmutationwas not observed in 208 chromosomes
from a German female control sample and 32 chromo-
somes from an appropriate British female control sample.
RT-PCR spanning exons 3 and 4, including the site of
mutation in the MECP2 gene, performed on RNA from
lymphoblastoid cell lines from probands II-6, III-1, III-7,
and III-8 (fig. 1A) did not show any difference between
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affected or unaffected family members (data not shown)
as was expected for a missense mutation.
Comparison of the clinical features of male patients
harboring the same A140Vmutation in theMECP2 gene
revealed similarities, besides moderate-to-severe MR, in
the family described here and that described elsewhere
(Orrico et al. 2000). Male patients of the family with
PPM-X showed pyramidal signs and parkinsonian fea-
tures (Lindsay et al. 1996), and affected males of the
other family were reported to have resting tremors and
slowness of movements (Orrico et al. 2000). The A140V
mutation was evident in all affected males of the PPM-
X family, whether they showed manic-depressive psy-
chosis in addition to MR or not (fig. 1A). The possibility
remains that such psychiatric features arose as a specific
feature of the abnormal MECP2 gene or as a side effect
of the MR phenotype and are not due to a mutation in
a second gene causing the manic-depressive psychoses.
The frequency and severity of the psychiatric features
make it less likely that they are a side effect of the MR
phenotype (Lindsay et al. 1996). For the two previously
described sporadic cases with the A140V mutation, no
clinical features other than moderate-to-severe MR have
been reported (Couvert et al. 2001). It was not stated
in the publication whether the patient who had addi-
tional psychiatric features harbored the A140V or one
of the other three reported mutations. If the former were
true, this would add to the phenotypic similarities found
between carriers of this specific mutation.
In addition, we examined the X inactivation status in
DNA from blood cells of the obligate carrier females
(I-1, II-3, II-19) and female II-13, who is not carrying the
mutation. One of the primers—either RS-6 or RS-7 (Me-
loni et al. 2000)—was fluorescently labeled, and the PCR
products of the CAG repeat of the androgen receptor gene
from HpaII digested and nondigested DNA (Allen et al.
1992) were run on an ABI 377 automatic sequencer (Ap-
plied Biosystems). The founder female I-1 was not infor-
mative for the polymorphism, but all other females
showed a random pattern of X inactivation in peripheral
blood leukocytes (data not shown). Therefore, the ran-
dom pattern of X inactivation and the mild form of MR
in the female heterozygous mutation carriers are further
similarities between both familial cases harboring the
A140V mutation. Additional phenotypic abnormali-
ties in females of the family reported by Orrico et al.
(2000)—such as microcephaly, asternic habitus with
poorly muscled build, speech difficulties, genu valgum,
and gait disturbance—have not been found in the family
with PPM-X. This raises the possibility that skewed X
inactivation might have occurred during developmental
processes and/or in tissues other than peripheral blood
lymphocytes. In addition, the healthy phenotype and
random X-inactivation pattern in peripheral blood lym-
phocytes of the mothers of the two sporadic cases, who
also carry the A140V mutation (Couvert al. (2001),
point to the possibility of neuronal mosaicism resulting
from skewed MECP2 expression. Overall, the mutated
amino acid 140, located in the middle of the methyl-
CpG binding–domain (MBD), would shorten the pre-
dicted a-helix length by half (Orrico et al. 2000). The
shortened a-helix could explain the harmful effect of
this mutation in hemizygous males. In addition, solution
structure modeling of the MECP2 MBD-DNA complex
located A140 relatively near the DNA backbone, and
the A140V mutation was considered to cause reduced
DNA-binding affinity through the introduction of val-
ine’s bulky side chain (Ohki et al. 2001).
In conclusion, we report here the genetic cause of the
PPM-X syndrome as a mutation in the MECP2 gene.
This is the second family withMR that included affected
individuals harboring the A140V mutation in the gene
and showing additional similar clinical features in the
affected males. The discovery of two further sporadic
MR cases with the same mutation strongly suggests that
A140V is a hot spot of mutation resulting in MR.
Accordingly, the occurrence of several mutations in
MECP2 resulting in MR in males should lead to a sys-
tematic screening of this gene in all unexplained cases
ofMR. The results also suggest that the A140Vmutation
in MECP2 has a role in the manic-depressive psychosis
in this family, and such a role would be worth investi-
gating further in patients with similar unexplained psy-
chiatric features. A simple and reliable PCR approach
has been developed for detection of the hot spot A140V
mutation, which is here recommended as the first screen-
ing step before any further exhaustive mutation analyses
of the coding region of the MECP2 gene.
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